Aging is a progressive and irreversible pathophysiological process that manifests in the decline of tissue and cellular functions and a significant increase in the risk of various aging-related diseases, including metabolic diseases. While advances in modern medicine have significantly improved human health and extended human lifespan, metabolic diseases such as obesity and type 2 diabetes in older adults pose a major challenge to global public health as societies age. Consequently, an appreciation of the intricate interplay between risk factors and metabolic diseases is of paramount importance for the promotion of well-being and healthy aging.
Fig. 1 The interactions between aging and metabolic diseases. (Szabo L, et al. 2020)
CD BioSciences provides trusted preclinical contract research services specializing in aging-related metabolic disease research and drug development. With years of experience in the industry, we offer a comprehensive range of services to support our client's research and development needs.
Our team of experts can assist in the development and customization of obesity animal models, including diet-induced obesity models and genetically modified models. we help clients evaluate the effects of potential therapeutic interventions on weight regulation, adipose tissue biology, and metabolic homeostasis in these models.
We provide an array of services to study T2D and its underlying mechanisms. We also offer comprehensive phenotypic assessments, including glucose tolerance tests, insulin sensitivity tests, and measurements of key metabolic parameters.
Our team can assist in the development of hypertension models, including genetic models and high-salt diet-induced models. We provide comprehensive assessments of blood pressure, vascular function, and cardiac parameters to evaluate potential therapeutic strategies for hypertension.
CD BioSciences offers a range of analysis services to decipher the pathogenic mechanisms underlying aging-related metabolic diseases, which is crucial for the development of effective therapeutic interventions.
Our team of experts develops customized biomarker discovery strategies to meet the specific needs of each client and project. We employ a multidisciplinary approach to aging biomarker identification, utilizing advanced technologies and techniques such as genomics, proteomics, metabolomics, and bioinformatics. We apply sophisticated statistical and bioinformatics tools to identify differentially expressed genes, proteins, or metabolites between aging-related metabolic disease and control groups. We employ bivariate correlation analysis to estimate the correlations between variables and age, and also to evaluate the relationship between metabolic biomarkers and aging-related diseases. Integrating and interpreting the data, we can pinpoint potential biomarkers that are significantly associated with aging-related metabolic disease progression, severity, or response to treatment.
We offer aging-related metabolic disease model customization services tailored to meet specific research needs. Utilizing various techniques, such as genetic modification, cell culture optimization, or induction of aging-related disease-like conditions, our team of experts can develop and customize experimental models that closely mimic the pathophysiological features of targeted aging-related metabolic diseases. We ensure that the disease models recapitulate key aspects of the human disease, including relevant metabolic dysregulation, pathological features, and functional abnormalities.
CD BioSciences is committed to supporting the drug discovery and development process for aging-related metabolic diseases. We begin by assisting clients in the identification and validation of potential therapeutic targets for aging-related metabolic diseases. We also offer preclinical development support to guide clients perform entire developmental processes. We conduct in vitro and in vivo pharmacology studies to evaluate the efficacy and safety of potential drug candidates. In vitro studies involve testing the candidates in cell-based assays or organoid systems to assess their effects on relevant disease pathways and endpoints. In vivo studies utilize animal models to evaluate the candidates' pharmacokinetics, efficacy, and toxicity profiles.
At CD BioSciences, through our specialized R&D services, we provide comprehensive solutions to support your research goals. Our team of highly skilled scientists and reliable technologies ensure high-quality data and results. If you are interested in our services, please feel free to contact us or make an online inquiry.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.